Yiming Wu

Yiming Wu

Auto-generated profile, based on publicly available information

Yiming Wu

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2016 in Science
Verified
Journal Article
Closed access
PDF file
LSLonglong Si
Longlong Si
HXHuan Xu
Huan Xu
XZXueying Zhou
Xueying Zhou
ZZZiwei Zhang
Ziwei Zhang
ZTZhenyu Tian
Zhenyu Tian
DZDemin Zhou
Demin Zhou
Genetic code expansion and orthogonal translation machinery are used to generate live, attenuated viral vaccines.

21 November 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MYMaorong Yu
Maorong Yu
LSLonglong Si
Longlong Si
YWYufei Wang
Yufei Wang
YWYiming Wu
Yiming Wu
FYFei Yu
Fei Yu
DZDemin Zhou
Demin Zhou

1 February 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SYShuhua Yi
Shuhua Yi
YYYuting Yan
Yuting Yan
MJMeiling Jin
Meiling Jin
Supriyo BhattacharyaSupriyo Bhattacharya
Supriyo Bhattacharya
YWYi Wang
Yi Wang
LWLili Wang
Lili Wang
Mantle cell lymphoma (MCL) is a phenotypically and genetically heterogeneous malignancy in which the genetic alterations determining clinical indications are not fully understood. Here, we performed a comprehensive whole-exome sequencing analysis of 152 primary samples derived from 134 MCL patients, including longitudinal samples from 16 patients and matched RNA-Seq data from 48 samples. We classified MCL into 4 robust clusters (C1–C4). C1 featured mutated immunoglobulin heavy variable (IGHV), CCND1 mutation, amp(11q13), and active B cell receptor (BCR) signaling. C2 was enriched with del(11q)/ATM mutations and upregulation of NF-κB and DNA repair pathways. C3 was characterized by mutations in SP140, NOTCH1, and NSD2, with downregulation of BCR signaling and MYC targets. C4 harbored del(17p)/TP53 mutations, del(13q), and del(9p), and active MYC pathway and hyperproliferation signatures. Patients in these 4 clusters had distinct outcomes (5-year overall survival [OS] rates for C1–C4 were 100%, 56.7%, 48.7%, and 14.2%, respectively). We also inferred the temporal order of genetic events and studied clonal evolution of 16 patients before treatment and at progression/relapse. Eleven of these samples showed drastic clonal evolution that was associated with inferior survival, while the other samples showed modest or no evolution. Our study thus identifies genetic subsets that clinically define this malignancy and delineates clonal evolution patterns and their impact on clinical outcomes.

1 March 2017 in Journal of Controlled Release
Verified
Journal Article
Closed access
LWLing Wu
Ling Wu
JCJingxian Chen
Jingxian Chen
YWYiming Wu
Yiming Wu
BZBo Zhang
Bo Zhang
XCXiaochun Cai
Xiaochun Cai
DZDemin Zhou
Demin Zhou

1 September 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MCMartina Cusan
Martina Cusan
HSHaifeng Shen
Haifeng Shen
BZBo Zhang
Bo Zhang
ALAijun Liao
Aijun Liao
LYLu Yang
Lu Yang
LWLili Wang
Lili Wang
RNA splicing factor SF3B1 is recurrently mutated in various cancers, particularly in hematologic malignancies. We previously reported that coexpression of Sf3b1 mutation and Atm deletion in B cells, but not either lesion alone, leads to the onset of chronic lymphocytic leukemia (CLL) with CLL cells harboring chromosome amplification. However, the exact role of Sf3b1 mutation and Atm deletion in chromosomal instability (CIN) remains unclear. Here, we demonstrated that SF3B1 mutation promotes centromeric R-loop (cen-R-loop) accumulation, leading to increased chromosome oscillation, impaired chromosome segregation, altered spindle architecture, and aneuploidy, which could be alleviated by removal of cen-R-loop and exaggerated by deletion of ATM. Aberrant splicing of key genes involved in R-loop processing underlay augmentation of cen-R-loop, as overexpression of the normal isoform, but not the altered form, mitigated mitotic stress in SF3B1-mutant cells. Our study identifies a critical role of splice variants in linking RNA splicing dysregulation and CIN and highlights cen-R-loop augmentation as a key mechanism for leukemogenesis.

17 April 2023 in Blood Cancer Discovery
Verified
Journal Article
Open access
PDF file
YWYiming Wu
Yiming Wu
MJMeiling Jin
Meiling Jin
MFMike Fernandez
Mike Fernandez
KHKevyn Hart
Kevyn Hart
ALAijun Liao
Aijun Liao
LWLili Wang
Lili Wang
RNA splicing dysregulation underlies the onset and progression of cancers. In chronic lymphocytic leukemia (CLL), spliceosome mutations leading to aberrant splicing occur in ∼20% of patients. However, the mechanism for splicing defects in spliceosome-unmutated CLL cases remains elusive. Through an integrative transcriptomic and proteomic analysis, we discover that proteins involved in RNA splicing are posttranscriptionally upregulated in CLL cells, resulting in splicing dysregulation. The abundance of splicing complexes is an independent risk factor for poor prognosis. Moreover, increased splicing factor expression is highly correlated with the abundance of METTL3, an RNA methyltransferase that deposits N6-methyladenosine (m6A) on mRNA. METTL3 is essential for cell growth in vitro and in vivo and controls splicing factor protein expression in a methyltransferase-dependent manner through m6A modification-mediated ribosome recycling and decoding. Our results uncover METTL3-mediated m6A modification as a novel regulatory axis in driving splicing dysregulation and contributing to aggressive CLL. Significance: METTL3 controls widespread splicing factor abundance via translational control of m6A-modified mRNA, contributes to RNA splicing dysregulation and disease progression in CLL, and serves as a potential therapeutic target in aggressive CLL. See related commentary by Janin and Esteller, p. 176. This article is highlighted in the In This Issue feature, p. 171